Elevance Health (ELV) Stock Forecast & Price Target

$400.69 -6.35 (-1.56%)

(As of 11/15/2024 ET)

Elevance Health - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 16 Analyst Ratings

Sell
1

Hold
2

Buy
13

Based on 16 Wall Street analysts who have issued ratings for Elevance Health in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 16 analysts, 1 has given a sell rating, 2 have given a hold rating, 12 have given a buy rating, and 1 has given a strong buy rating for ELV.

Consensus Price Target

$539.20
34.57% Upside

According to the 16 analysts' twelve-month price targets for Elevance Health, the average price target is $539.20. The highest price target for ELV is $649.00, while the lowest price target for ELV is $478.00. The average price target represents a forecasted upside of 34.57% from the current price of $400.69.

ELV Analyst Ratings Over Time

Type	Current Forecast 11/17/23 to 11/16/24	1 Month Ago 10/18/23 to 10/17/24	3 Months Ago 8/19/23 to 8/18/24	1 Year Ago 11/17/22 to 11/17/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	12 Buy rating(s)	13 Buy rating(s)	13 Buy rating(s)	10 Buy rating(s)
Hold	2 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	2 Hold rating(s)
Sell	1 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$539.20	$605.07	$604.29	$565.82
Forecasted Upside	34.57% Upside	35.64% Upside	11.14% Upside	22.22% Upside
Consensus Rating	Moderate Buy	Buy	Buy	Moderate Buy

Tech funds are hemorrhaging cash: Sell this stock now (Ad)

Something very strange is happening to U.S. stocks following President Trump's victory... And this could spell disaster for some of America's favorite tech companies.

You can watch for it for free, right here.

ELV Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ELV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Elevance Health Stock vs. The Competition

Type	Elevance Health	Medical Companies	S&P 500
Consensus Rating Score	2.81	2.80	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	34.54% Upside	28,534.31% Upside	9.87% Upside
News Sentiment Rating	Positive News See Recent ELV News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/5/2024	Mizuho 2 of 5 stars		Lower Target	Outperform ➝ Outperform	$585.00 ➝ $505.00	+21.18%
11/4/2024	Wells Fargo & Company 3 of 5 stars		Lower Target	Overweight ➝ Overweight	$593.00 ➝ $495.00	+19.56%
10/23/2024	Morgan Stanley 3 of 5 stars		Lower Target	Overweight ➝ Overweight	$643.00 ➝ $551.00	+31.24%
10/22/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$622.00 ➝ $501.00	+19.06%
10/21/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$589.00 ➝ $484.00	+12.56%
10/18/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Sarah James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Target		$485.00	+12.18%
Shocking footage from Bill Gates’ $100,000,000,000 AI Bet (Ad) If you missed out on Nvidia, watch this BEFORE November 19th. Click here for the full video
10/18/2024	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Fidel Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Underperform ➝ Underperform
10/18/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$605.00 ➝ $555.00	+28.06%
10/18/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$585.00 ➝ $478.00	+9.02%
10/18/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$620.00 ➝ $520.00	+18.60%
10/18/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$600.00 ➝ $485.00	+8.72%
10/18/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Toung Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
7/18/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Neutral	$646.00 ➝ $530.00	+1.89%
5/30/2024	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Ha Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/30/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$628.00 ➝ $631.00	+24.00%
5/30/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$649.00	+28.38%
4/19/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$602.00 ➝ $604.00	+15.01%
7/12/2023	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Peer Perform
4/27/2023	22nd Century Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Upgrade
4/21/2023	Loop Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy	$565.00 ➝ $550.00	+20.90%
4/20/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$571.00 ➝ $575.00	+25.73%
1/26/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	W. Mayo Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$580.00	+17.03%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 04:36 PM ET.

ELV Forecast - Frequently Asked Questions

: According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for Elevance Health is $539.20, with a high forecast of $649.00 and a low forecast of $478.00.
: 16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Elevance Health in the last year. There is currently 1 sell rating, 2 hold ratings, 12 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ELV shares.
: According to analysts, Elevance Health's stock has a predicted upside of 34.57% based on their 12-month stock forecasts.
: Over the previous 90 days, Elevance Health's stock had 1 downgrade by analysts.
: Elevance Health has been rated by research analysts at Argus, Barclays, Cantor Fitzgerald, Mizuho, Morgan Stanley, Raymond James, Royal Bank of Canada, Stephens, TD Cowen, Truist Financial, UBS Group, and Wells Fargo & Company in the past 90 days.
: Analysts like Elevance Health more than other "medical" companies. The consensus rating score for Elevance Health is 2.81 while the average consensus rating score for "medical" companies is 2.80. Learn more on how ELV compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Tech funds are hemorrhaging cash: Sell this stock now (Ad)

Something very strange is happening to U.S. stocks following President Trump's victory... And this could spell disaster for some of America's favorite tech companies.

You can watch for it for free, right here.

This page (NYSE:ELV) was last updated on 11/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Elevance Health (ELV) Stock Forecast & Price Target